Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer

• Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced that the Phase 3 IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis.

• The study evaluates Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence.

• The Tecentriq combination showed a statistically significant improvement in RFS in the intention-to-treat population of HCC patients with an increased risk of recurrence following resection or ablation with curative intent, compared with active surveillance.

• Overall survival data were immature at the interim analysis, and follow-up will continue to the next analysis.

• Safety for Tecentriq and Avastin was consistent with the known safety profile of each therapeutic agent and with the underlying disease.

• Results from the IMbrave050 study will be discussed with health authorities and presented at an upcoming medical meeting.

• The IMbrave050 study randomized 662 people.

• Genentech has an extensive development program for Tecentriq, alone and in combination, including multiple ongoing and planned Phase 3 studies across different lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers.

• Price Action: RHHBY shares closed lower by 0.45% at $39.73 on Wednesday.

• Photo Via Company

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.